Who are Eperisone hydrochloride and Diclofenac sodium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Thiocolchicoside+Ketoprofen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eperisone-hydrochloride-and-diclofenac-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Eperisone hydrochloride and Diclofenac sodium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eperisone hydrochloride and Diclofenac sodium (Eperisone hydrochloride and Diclofenac sodium) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscle relaxant + NSAID combination. Area: Pain Management / Musculoskeletal Disorders.

phase 3 Muscle relaxant + NSAID combination Monoamine reuptake (eperisone); COX-1/COX-2 (diclofenac) Pain Management / Musculoskeletal Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Eperisone hydrochloride and Diclofenac sodium (Eperisone hydrochloride and Diclofenac sodium) — Eisai Co., Ltd.. This combination product uses eperisone as a muscle relaxant and diclofenac as an NSAID to reduce muscle tension and inflammation-related pain.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eperisone hydrochloride and Diclofenac sodium TARGET	Eperisone hydrochloride and Diclofenac sodium	Eisai Co., Ltd.	phase 3	Muscle relaxant + NSAID combination	Monoamine reuptake (eperisone); COX-1/COX-2 (diclofenac)
Thiocolchicoside+Ketoprofen	Thiocolchicoside+Ketoprofen	Sanofi	phase 3	Muscle relaxant + NSAID combination	GABA-A receptor (thiocolchicoside); COX-1/COX-2 (ketoprofen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscle relaxant + NSAID combination class)

Eisai Co., Ltd. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eperisone hydrochloride and Diclofenac sodium — Competitive Intelligence Brief. https://druglandscape.com/ci/eperisone-hydrochloride-and-diclofenac-sodium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab